Episode 54: The GLP-1 Conversation Nobody's Having Yet (Part 1 of 3): New research, new generics, and the truth behind the headlines

Send us your questions & commentsIn the first episode of her three-part August series, Joanne Willis opens up an honest, balanced conversation about GLP-1 medications (Ozempic, Wegovy, Mounjaro and the new generics coming to market). Joanne walks through a June 2026 Stanford study on "food noise" and highlights something the headlines mostly missed - how to make the most of that food freedom. She shares in simple, plain language, the four remarkable ways these medications work with the body but then goes on to explain why GLP-1s can't do all the work alone, and what is just as important for us to consider for true health and sustainable weight loss for many years to come. Links & Resources:1. Stanford Center for Digital Health "food noise" study (JAMA Network Open, June 2026): Link: https://medicine.stanford.edu/news/stories/2026/06/GLP1-Experiences.html2. Register for our live, virtual workshop, "Ozempic & GLP-1s - How to Get the Benefits Without the Side Effects" on August 19th at 7pm EST HERE.Ready to get clarity on what's going on inside your body? Book your Complimentary Health Audit with Joanne Here. We'll look at your unique situation, identify where your key metabolic imbalances might be and create a roadmap for reclaiming your energy and health — naturally and sustainably. No obligation. Just real answers.Want to learn more about The Metabolic Balance Program - the program I use in my practice to get my client real results that last? Discover what everyone is talking about! The world's leading personalized nutrition and hormone-balancing system with the highest global success rate for sustainable weight loss and health transformation without pills, shakes or expensive proprietary foods.One nutrition plan based on YOUR bloodwork. No deprivation. No one-size-fits-all diet. Just real food matched to your own biochemistry for real, lasting results.Watch the information video here.